Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 113
Selected: 0
NCT IDTitle
NCT01755650Phase 0 of 18F FPM Using PET/CT in Patients With a Variety of Malignancies
NCT05864742Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma
NCT04430192Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
NCT03299660Avelumab With Chemoradiation in Locally Advanced Rectal Cancer
NCT06812715Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
NCT04769817ProsTIC Registry of Men Treated With PSMA Theranostics
NCT05570227Metabolic Phenotypes in Melanoma
NCT07090369Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer
NCT03874884177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
NCT03429387PET/CT and Bacterial/Fungal PCR in High Risk Febrile Neutropenia
NCT05592938Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
NCT06480396High Versus Lower Intensity Surveillance Following Resection of Retroperitoneal Sarcoma
NCT04234061Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma
NCT05383079Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer
NCT07527819Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)
NCT05878288Deep sequencIng in Cutaneous Squamous CEll caRciNomas
NCT03658447PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)
NCT05169177Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy
NCT04914741A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)
NCT07387978A Study to Describe the Effect of Photobiomodulation (Low Level Laser Therapy) in Reducing the Severity and Incidence of Oral Mucositis (Oral Ulceration) in Oral Cancer Patients Undergoing Radiation Treatment
NCT00335348Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse
NCT06127654Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy
NCT03806764Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient
NCT06414148MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
NCT00422864A Single Arm Trial of Oxaliplatin and 5FU With Concurrent Radiation in Patients With Metastatic Rectal Cancer
NCT00234169A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone
NCT01742793An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)
NCT05899985Magnetic Sentinel Lymph Node Mapping in Upper Gastro-Intestinal Cancer: A Feasibility Clinical Investigation
NCT07241715Conversion Surgery for Gastric Cancer With Peritoneal Metastases (CONVERGENCE)
NCT03307759Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma
NCT01500538A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)
NCT05983159A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
NCT04819607The Evaluating Multidisciplinary Bone Marrow Failure Care in Bone Marrow Failure and Related Disorders.
NCT06882499Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II
NCT03161756Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma
NCT01486459A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer
NCT04918810Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT04619147Invasive Fungal Infections in Patients Following Stem Cell Transplant
NCT00193934Magnetic Resonance Imaging (MRI) Staging of Cervix Cancer
NCT05666700CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study
NCT04319783Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
NCT05053854PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours
NCT05263700FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary
NCT05154162PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI
NCT00482261A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression
NCT01488565A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia
NCT05340374Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer
NCT04074460Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study
NCT05184790LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology
NCT03331731A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma